LINAS RIAUBA: Open Payments
NPI 1477645273 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,115 in 25 payments from 9 companies in 2025. Trend: 2023 $223 · 2024 $383 · 2025 $1,115
Consulting: $630Food & beverage: $485
| Company | Payments | Amount |
|---|---|---|
| CIPLA USA INC. | 1 | $362 |
| Cepheid | 1 | $268 |
| Gilead Sciences, Inc. | 10 | $268 |
| Insmed, Inc. | 4 | $64 |
| ViiV Healthcare Company | 3 | $48 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $32 |
| Theratechnologies Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
Products named: Biktarvy, Arikayce, XIFAXAN, APRETUDE, AREXVY, TRELEGY ELLIPTA, EGRIFTA, CABENUVA.
Industry payments across NJ — which companies pay providers there.
